DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
A lyophilized open-source RT-LAMP assay for molecular diagnostics in resource-limited settings
A critical bottleneck for equitable access to population-scale molecular diagnostics is the limited availability of rapid, inexpensive point-of-care tests, especially in low- and middle-income countries. Here, we developed an open-source reverse transcription loop-mediated isothermal amplification (RT-LAMP) molecular assay for pathogen detection. It is based on nonproprietary enzymes, namely, HIV-1 reverse transcriptase, Bst LF DNA polymerase, and UDG BMTU thermolabile uracil-DNA glycosylase. Formulated as liquid or lyophilized reaction mixtures, these reagents enable sensitive colorimetric detection of respiratory samples without the need for prior nucleic acid isolation. We evaluated our lyophilized RT-LAMP assay on clinical samples with suspected COVID-19 infection, demonstrating high sensitivity and 100% specificity compared with the gold-standard RT-qPCR. Reaction performance was unaffected by prolonged storage of lyophilized reagents at ambient or elevated temperatures. As a proof of concept, we evaluated the robustness and ease of use of lyophilized RT-LAMP reaction mixes through independent laboratory testing of COVID-19 samples in Ghana. Overall, our open-source RT-LAMP assay provides a flexible and scalable point-of-care test that can be adapted for rapid detection of various pathogens in resource-limited settings., This work would not have been possible without the enthusiastic support of
the IMBA, IMP, and WACCBIP research institutes, as well as the many volunteers and partners of the VCDI, who came together to help and collaborate under the exceptional circumstances of the COVID-19 pandemic.
We thank the Pauli, Brennecke, and Penninger groups for sharing laboratory
space and reagents. We thank Nathan Tanner (NEB) for valuable discussions, sharing important information on LAMP technology, and feedback on
the article, Stuart Le Grice and Jennifer Miller (NIH/NCI) for helpful advice
and reagents for the expression of HIV-RTs, and Jennifer C Molloy (University
of Cambridge) for useful discussion. We thank TReND in Africa for initiating
the collaboration between our laboratories in Vienna and Ghana, and Jochen Wittbrodt, Ute Volbehr, Kevin Urbansky, and Eva Hasel for administering the VW funding. We also thank Kim and Anna Nasmyth for their
generous support of the project via the “Mila Charitable Organisation”. We
are grateful to the COVID Testing Scaleup Slack channel for openly sharing
and exchanging information. M Matl and MJ Kellner were supported by the
Vienna Science and Technology Fund (WWTF) through project COV20-031.
This project received funding from the VW foundation (grant # 9A027) given
to TReND in Africa, as well as funding from the “Mila Charitable Organisation”. The IMP receives generous institutional funding from Boehringer
Ingelheim and the Austrian Research Promotion Agency (Headquarter grant
FFG-852936), and IMBA is generously supported by the Austrian Academy of
Sciences. Research in the laboratory of A Pauli was supported by the
Austrian Science Fund (START Projekt Y 1031-B28, SFB “RNA-Deco” F 80) and
by the European Research Council (CoG 101044495/GaMe). Research in the
laboratory of J Brennecke was supported by the European Research Council
(ERC2015-CoG - 682181). F Ansah and GA Awandare were supported by a
Science for Africa Foundation (SFA)/Wellcome Developing Excellence in
Leadership Training and Science (DELTAS) in Africa grant (DEL-22-014: GA
Awandare). Work in the L Menendez-Arias ´ laboratory was supported by
grant PID2022-136725OB-I00/AEI/10.13039/501100011033 of the Spanish
Ministry of Science, Innovation and Universities, and an institutional grant
of Fundación Ramón Areces. The laboratory of JM Penninger at IMBA received funding from the Austrian Academy of Sciences, the Medical University of Vienna, the Swedish Research Council (2018-05766), the T. von
Zastrow foundation, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 101005026. This Joint Undertaking
receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA, Peer reviewed
Proyecto:
EC / H2020 101005026
,
EC / H2020 682181
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-136725OB-I00
DOI: http://hdl.handle.net/10261/429042, https://api.elsevier.com/content/abstract/scopus_id/105011504922
HANDLE: http://hdl.handle.net/10261/429042, https://api.elsevier.com/content/abstract/scopus_id/105011504922